These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17033447)

  • 1. Imatinib mesylate-induced acute hepatitis with autoimmune features.
    Dhalluin-Venier V; Besson C; Dimet S; Thirot-Bibault A; Tchernia G; Buffet C
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1235-7. PubMed ID: 17033447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib-induced immune hepatitis: case report and literature review.
    Al Sobhi E; Zahrani Z; Zevallos E; Zuraiki A
    Hematology; 2007 Feb; 12(1):49-53. PubMed ID: 17364993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 4. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 6. [Imatinib mesylate-induced acute cytolytic hepatitis].
    Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
    [No Abstract]   [Full Text] [Related]  

  • 7. An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient.
    Aliberti S; Grignani G; Allione P; Fizzotti M; Galatola G; Pisacane A; Aglietta M
    Am J Clin Oncol; 2009 Dec; 32(6):640-1. PubMed ID: 19955903
    [No Abstract]   [Full Text] [Related]  

  • 8. Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
    Nicolini FE; Hayette S; Legros L; Rousselot P; Maloisel F; Tulliez M; Guerci A; Charbonnier A; Prébet T; Rigal-Huguet F; Chabane K; Magaud JP; Paillet C; Pivot C; Michallet M
    Leuk Res; 2011 Jan; 35(1):80-6. PubMed ID: 20605207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
    Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
    Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
    Pasmatzi E; Monastirli A; Matsouka P; Tsambaos D
    Acta Derm Venereol; 2003; 83(5):391-2. PubMed ID: 14609118
    [No Abstract]   [Full Text] [Related]  

  • 11. Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
    Ferrero D; Pogliani EM; Rege-Cambrin G; Fava C; Mattioli G; Dellacasa C; Campa E; Perfetti P; Fumagalli M; Boccadoro M
    Haematologica; 2006 Jun; 91(6 Suppl):ECR27. PubMed ID: 16785130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
    J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 15. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
    Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.
    Ohyashiki K; Kuriyama Y; Nakajima A; Tauchi T; Ito Y; Miyazawa H; Kimura Y; Serizawa H; Ebihara Y
    Leukemia; 2002 Oct; 16(10):2160-1. PubMed ID: 12357373
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 19. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.